BMS Reyataz complaint presages easier exclusivity enforcement in 'tricky' markets?
This article was originally published in Scrip
Voluntary license agreements could become an increasingly popular means for originator companies to protect brand exclusivity in global markets where there is money to be made but little protection for intellectual property rights. A breach of contract complaint brought by Bristol-Myers Squibb in the US against Mylan/Matrix will put the theory to the test.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.